July 26th 2021
press releases
July 21st 2021
press releases
July 16th 2021
analyst reports
July 14th 2021
analyst reports
July 13th 2021
press releases
This research report is intended for use only by persons who qualify as professional investors or eligible counterparties (institutional investors) in the applicable jurisdiction, and not by any private individuals or other persons who qualify as retail clients.
July 6th 2021
analyst reports
Upcoming Events
Whats next.
September 17th 2021 - September 21st 2021
read more
September 27th 2021 - September 30th 2021
read more
November 10th 2021 - November 14th 2021
read more
passion.
It takes a great deal of passion to pursue the fight against cancer and autoimmune diseases. We put our heart and soul into winning it.
know-how.
Our goal is to gather the strongest forces, the brightest minds and the most dedicated employees.
research.
Accurate research and development is the strongest foundation for developing effective treatments.
What is LAG-3?
Lymphocyte-activation gene 3, or LAG-3 (LAG-3), is a gene that provides the genetic information to make a cell surface molecule with biologic effects on T cell function.
LAG-3 is being used for many immunotherapy treatments including Eftilagimod Alpha from Immutep.
